PUMA Celebrates its 75th Anniversary and Rich History in Motorsport
3.3.2023 16:16:00 EET | Business Wire | Press release
Sports company PUMA kicked off the 2023 Formula 1 season with a special panel discussion to celebrate its legacy in Motorsport culture and discuss the importance of innovations in racewear production. It was the first of a series of events to mark PUMA’s 75th anniversary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005219/en/
Panel Talk ahead of the 2023 Formula 1 season to celebrate PUMAs legacy in Motorsport culture. (Photo: Business Wire)
Founded in 1948, PUMA has been at the forefront of innovation throughout its history, pushing the boundaries of what is possible in performance, functionality, and design. PUMA's rich history in motorsport dates back to 2001, when JORDAN GRAND PRIX became the first Formula 1 racing team that PUMA supplied with both footwear and clothing. Since then, PUMA has collaborated with some of the biggest names in the sport, including Michael Schumacher and Lewis Hamilton, and produced the best product for the best teams like Mercedes-AMG Petronas F1, Scuderia Ferrari and Red Bull Racing.
The panel talk was held in Bahrain on March 1 and was moderated by Noemi de Miguel, a sports journalist and television presenter for DAZN together with experts — Thomas Josnik (Global Director Motorsport, PUMA), Mick Schumacher (Mercedes-AMG Petronas F1 Team Reserve driver), Gregor Huebner (Senior Manager Sports Marketing Motorsport, PUMA) and Maurizio Sicco (Consultant in Motorsport racewear, PUMA) — they explored PUMA’s milestones in motorsport, discussed racing products from different eras, and spoke about what motorsport represents today.
PUMA’s latest racing shoes, SPEEDCAT PRO, were designed based on functionality to support drivers in their high performance on track. Years of innovation and technology packed into a single shoe, the SPEEDCAT PRO uses state of the art materials for racing. The upper and lining are made of lightweight fabric for speed, comfort, and of course fire protection. To guarantee absolute control of the pedals, the SPEEDCAT PRO comes with a low-profile rubber outsole and an EVA wedge provides just the right amount of comfort while keeping the shoe light and nimble. The SPEEDCAT PRO was built in compliance with the latest FIA Homologation Regulations for Safety Equipment (FIA Standard 8856-2018) for the best protection in racing. The SPEEDCAT PRO also includes several design elements that pay homage to PUMA's racing heritage.
“PUMA is proud to celebrate its 75th anniversary this year and also our legacy in motorsport industry”, said Thomas Josnik Global Director Motorsport at PUMA. “Innovation, speed, and technology have always been at the heart of everything we do, and this event is a tribute to our commitment to pushing boundaries and driving change in the industry.”
The event was an exciting first step in this year of celebration of 75 years of PUMA's past, present, and future in motorsport, highlighting the brand's commitment to excellence and innovation in racewear.
Event recap (YouTube): HERE
Event pictures: HERE
PUMA 75 Lewis Hamilton Interview: HERE
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling, and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 18,300 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005219/en/
Contact information
PUMA
Gudrun Cämmerer
Teamhead Global Brand PR
gudrun.caemmerer@puma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom